Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVEAL 1: VGX-3100 and Electroporation for Cervical HSIL
TCTR20170301001Phase 3Active, not recruiting
- Sponsor
- Inovio Pharmaceuticals, Inc.
- Start
- Jun 2017
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of bizalimogene ralaplasmid in cervical intraepithelial neoplasia (CIN), sponsored by Inovio Pharmaceuticals, Inc.. Started Jun 2017; status: active, not recruiting.
02
Drugs
bizalimogene ralaplasmid
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on TCTR20170301001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20170301001.